Straightforward study design: SPARTAN trial of apalutamide for nmCRPC
Description: There has previously been no effective treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC). Now there are several exciting late-phase clinical trials investigating promising treatments for nmCRPC, which are likely to be in the clinic soon. In this interview, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of the Phase III double-blind SPARTAN trial (NCT01946204), which tested apalutamide in this group. Dr Small explains the straightforward design of the study, including the inclusion criteria. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.
Shared By : VJOncology
Posted on : 02/12/18
Added : 6 days ago